1	3	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Discussion	_	_	NN	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	statistical	_	_	JJ	_	_	_	_	_
3	analysis	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	collected	_	_	VBN	_	_	_	_	_
7	data	_	_	NNS	_	_	_	_	_
8	at	_	_	IN	_	_	_	_	_
9	each	_	_	DT	_	_	_	_	_
10	visit	_	_	NN	_	_	_	_	_
11	shows	_	_	VBZ	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	very	_	_	RB	_	_	_	_	_
14	good	_	_	JJ	_	_	_	_	_
15	trend	_	_	NN	_	_	_	_	_
16	for	_	_	IN	_	_	_	_	_
17	hydrogel	_	_	NN	_	_	_	_	_
18	containing	_	_	VBG	_	_	_	_	_
19	trehalose	_	_	NN	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	ceramides	_	_	NNS	_	_	_	_	_
22	based	_	_	VBN	_	_	_	_	_
23	ingredient	_	_	NN	_	_	_	_	_
24	at	_	_	IN	_	_	_	_	_
25	each	_	_	DT	_	_	_	_	_
26	visit	_	_	NN	_	_	_	_	_
27	:	_	_	:	_	_	_	_	_


1	Evaporimetry	_	_	NNP	_	_	_	_	_
2	(	_	_	-LRB-	_	_	_	_	_
3	Transepidermal	_	_	NNP	_	_	_	_	_
4	Water	_	_	NNP	_	_	_	_	_
5	Loss	_	_	NNP	_	_	_	_	_
6	(	_	_	-LRB-	_	_	_	_	_
7	TEWL	_	_	NNP	_	_	_	_	_
8	)	_	_	-RRB-	_	_	_	_	_
9	)	_	_	-RRB-	_	_	_	_	_


1	Evaporimetry	_	_	NNP	_	_	_	_	_
2	was	_	_	VBD	_	_	_	_	_
3	used	_	_	VBN	_	_	_	_	_
4	to	_	_	TO	_	_	_	_	_
5	detect	_	_	VB	_	_	_	_	_
6	any	_	_	DT	_	_	_	_	_
7	influence	_	_	NN	_	_	_	_	_
8	on	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	water	_	_	NN	_	_	_	_	_
11	barrier	_	_	NN	_	_	_	_	_
12	function	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	skin	_	_	NN	_	_	_	_	_
16	following	_	_	VBG	_	_	_	_	_
17	application	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	ceramides	_	_	NNS	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	trehalose	_	_	NN	_	_	_	_	_
22	based	_	_	VBN	_	_	_	_	_
23	ingredient	_	_	NN	_	_	_	_	_
24	hydrogel	_	_	NN	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	placebo	_	_	NN	_	_	_	_	_
27	hydrogel	_	_	NN	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	Corneometry	_	_	NN	_	_	_	_	_
2	(	_	_	-LRB-	_	_	_	_	_
3	Hydration	_	_	NN	_	_	_	_	_
4	)	_	_	-RRB-	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	order	_	_	NN	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	measure	_	_	VB	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	amount	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	water	_	_	NN	_	_	_	_	_
9	present	_	_	JJ	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	stratum	_	_	NN	_	_	_	_	_
13	corneum	_	_	NN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	skin	_	_	NN	_	_	_	_	_
17	barrier	_	_	NN	_	_	_	_	_
18	condition	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	hydration	_	_	NN	_	_	_	_	_
21	has	_	_	VBZ	_	_	_	_	_
22	been	_	_	VBN	_	_	_	_	_
23	evaluated	_	_	VBN	_	_	_	_	_
24	through	_	_	IN	_	_	_	_	_
25	Corneometry	_	_	NNP	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Moreover	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	T-test	_	_	NN	_	_	_	_	_
5	applied	_	_	VBD	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	hydrogel	_	_	NN	_	_	_	_	_
8	containing	_	_	VBG	_	_	_	_	_
9	ceramides	_	_	NNS	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	trehalose	_	_	NN	_	_	_	_	_
12	based	_	_	VBN	_	_	_	_	_
13	ingredient	_	_	NN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	placebo	_	_	NN	_	_	_	_	_
16	formula	_	_	NN	_	_	_	_	_
17	gave	_	_	VBD	_	_	_	_	_
18	a	_	_	DT	_	_	_	_	_
19	statistically	_	_	RB	_	_	_	_	_
20	significant	_	_	JJ	_	_	_	_	_
21	difference	_	_	NN	_	_	_	_	_
22	between	_	_	IN	_	_	_	_	_
23	them	_	_	PRP	_	_	_	_	_
24	at	_	_	IN	_	_	_	_	_
25	each	_	_	DT	_	_	_	_	_
26	visit	_	_	NN	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	always	_	_	RB	_	_	_	_	_
29	showing	_	_	VBG	_	_	_	_	_
30	better	_	_	JJR	_	_	_	_	_
31	results	_	_	NNS	_	_	_	_	_
32	for	_	_	IN	_	_	_	_	_
33	the	_	_	DT	_	_	_	_	_
34	hydrogel	_	_	NN	_	_	_	_	_
35	containing	_	_	VBG	_	_	_	_	_
36	ceramides	_	_	NNS	_	_	_	_	_
37	and	_	_	CC	_	_	_	_	_
38	trehalose	_	_	NN	_	_	_	_	_
39	based	_	_	VBN	_	_	_	_	_
40	ingredient	_	_	NN	_	_	_	_	_
41	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	double-blind	_	_	JJ	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	placebo-controlled	_	_	JJ	_	_	_	_	_
5	study	_	_	NN	_	_	_	_	_
6	was	_	_	VBD	_	_	_	_	_
7	performed	_	_	VBN	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	assess	_	_	VB	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	by	_	_	IN	_	_	_	_	_
12	corneometry	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	evaporimetry	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	barrier	_	_	NN	_	_	_	_	_
18	normalizing	_	_	VBG	_	_	_	_	_
19	efficacy	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	a	_	_	DT	_	_	_	_	_
22	topical	_	_	JJ	_	_	_	_	_
23	product	_	_	NN	_	_	_	_	_
24	containing	_	_	VBG	_	_	_	_	_
25	trehalose	_	_	NN	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	ceramides	_	_	NNS	_	_	_	_	_
28	to	_	_	TO	_	_	_	_	_
29	alleviate	_	_	VB	_	_	_	_	_
30	skin	_	_	NN	_	_	_	_	_
31	dryness	_	_	NN	_	_	_	_	_
32	on	_	_	IN	_	_	_	_	_
33	limbs	_	_	NNS	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	study	_	_	NN	_	_	_	_	_
3	results	_	_	NNS	_	_	_	_	_
4	show	_	_	VBP	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	significant	_	_	JJ	_	_	_	_	_
7	moisturizing	_	_	VBG	_	_	_	_	_
8	effect	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	ingredient	_	_	NN	_	_	_	_	_
12	at	_	_	IN	_	_	_	_	_
13	each	_	_	DT	_	_	_	_	_
14	visit	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	both	_	_	CC	_	_	_	_	_
17	versus	_	_	IN	_	_	_	_	_
18	baseline	_	_	NN	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	versus	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	placebo	_	_	NN	_	_	_	_	_
23	control	_	_	NN	_	_	_	_	_
24	(	_	_	-LRB-	_	_	_	_	_
25	p	_	_	NN	_	_	_	_	_
26	<	_	_	SYM	_	_	_	_	_
27	0.01	_	_	CD	_	_	_	_	_
28	)	_	_	-RRB-	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	application	_	_	NN	_	_	_	_	_
4	site	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	topical	_	_	JJ	_	_	_	_	_
7	cosmetic	_	_	JJ	_	_	_	_	_
8	formula	_	_	NN	_	_	_	_	_
9	containing	_	_	VBG	_	_	_	_	_
10	a	_	_	DT	_	_	_	_	_
11	trehalose	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	ceramides	_	_	NNS	_	_	_	_	_
14	based	_	_	VBN	_	_	_	_	_
15	ingredient	_	_	NN	_	_	_	_	_
16	:	_	_	:	_	_	_	_	_


1	(	_	_	-LRB-	_	_	_	_	_
2	1	_	_	CD	_	_	_	_	_
3	)	_	_	-RRB-	_	_	_	_	_
4	Transepidermal	_	_	NN	_	_	_	_	_
5	water	_	_	NN	_	_	_	_	_
6	loss	_	_	NN	_	_	_	_	_
7	(	_	_	-LRB-	_	_	_	_	_
8	TEWL	_	_	NN	_	_	_	_	_
9	)	_	_	-RRB-	_	_	_	_	_
10	value	_	_	NN	_	_	_	_	_
11	shows	_	_	VBZ	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	reduction	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	−54	_	_	CD	_	_	_	_	_
16	%	_	_	NN	_	_	_	_	_
17	after	_	_	IN	_	_	_	_	_
18	4	_	_	CD	_	_	_	_	_
19	weeks	_	_	NNS	_	_	_	_	_
20	(	_	_	-LRB-	_	_	_	_	_


1	Figure	_	_	NN	_	_	_	_	_
2	2	_	_	CD	_	_	_	_	_


1	)	_	_	-RRB-	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	(	_	_	-LRB-	_	_	_	_	_
2	2	_	_	CD	_	_	_	_	_
3	)	_	_	-RRB-	_	_	_	_	_
4	Hydration	_	_	NN	_	_	_	_	_
5	shows	_	_	VBZ	_	_	_	_	_
6	an	_	_	DT	_	_	_	_	_
7	increase	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	102	_	_	CD	_	_	_	_	_
10	%	_	_	NN	_	_	_	_	_
11	after	_	_	IN	_	_	_	_	_
12	4	_	_	CD	_	_	_	_	_
13	weeks	_	_	NNS	_	_	_	_	_
14	(	_	_	-LRB-	_	_	_	_	_


1	Figure	_	_	NN	_	_	_	_	_
2	3	_	_	CD	_	_	_	_	_


1	)	_	_	-RRB-	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Such	_	_	JJ	_	_	_	_	_
2	results	_	_	NNS	_	_	_	_	_
3	point	_	_	VBP	_	_	_	_	_
4	out	_	_	RP	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	significant	_	_	JJ	_	_	_	_	_
7	moisturizing	_	_	VBG	_	_	_	_	_
8	effect	_	_	NN	_	_	_	_	_
9	after	_	_	IN	_	_	_	_	_
10	using	_	_	VBG	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	cosmetic	_	_	JJ	_	_	_	_	_
13	under	_	_	IN	_	_	_	_	_
14	examination	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	go	_	_	VB	_	_	_	_	_
17	well	_	_	RB	_	_	_	_	_
18	with	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	rationale	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	formulation	_	_	NN	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	based	_	_	VBN	_	_	_	_	_
26	on	_	_	IN	_	_	_	_	_
27	ingredients	_	_	NNS	_	_	_	_	_
28	able	_	_	JJ	_	_	_	_	_
29	to	_	_	TO	_	_	_	_	_
30	moisturize	_	_	VB	_	_	_	_	_
31	rapidly	_	_	RB	_	_	_	_	_
32	the	_	_	DT	_	_	_	_	_
33	skin	_	_	NN	_	_	_	_	_
34	and	_	_	CC	_	_	_	_	_
35	recover	_	_	VB	_	_	_	_	_
36	the	_	_	DT	_	_	_	_	_
37	cutaneous	_	_	JJ	_	_	_	_	_
38	barrier	_	_	NN	_	_	_	_	_
39	to	_	_	TO	_	_	_	_	_
40	allow	_	_	VB	_	_	_	_	_
41	it	_	_	PRP	_	_	_	_	_
42	to	_	_	TO	_	_	_	_	_
43	better	_	_	RBR	_	_	_	_	_
44	hold	_	_	VB	_	_	_	_	_
45	the	_	_	DT	_	_	_	_	_
46	water	_	_	NN	_	_	_	_	_
47	present	_	_	JJ	_	_	_	_	_
48	into	_	_	IN	_	_	_	_	_
49	its	_	_	PRP$	_	_	_	_	_
50	outer	_	_	JJ	_	_	_	_	_
51	layers	_	_	NNS	_	_	_	_	_
52	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	vivo	_	_	NN	_	_	_	_	_


1	evaluation	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	efficacy	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	formulation	_	_	NN	_	_	_	_	_
8	for	_	_	IN	_	_	_	_	_
9	atopic	_	_	JJ	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	very	_	_	RB	_	_	_	_	_
12	dry	_	_	JJ	_	_	_	_	_
13	skin	_	_	NN	_	_	_	_	_
14	(	_	_	-LRB-	_	_	_	_	_
15	Xerosis	_	_	NNP	_	_	_	_	_
16	)	_	_	-RRB-	_	_	_	_	_
17	was	_	_	VBD	_	_	_	_	_
18	done	_	_	VBN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	An	_	_	DT	_	_	_	_	_
2	example	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	one	_	_	CD	_	_	_	_	_
5	topical	_	_	JJ	_	_	_	_	_
6	formulation	_	_	NN	_	_	_	_	_
7	for	_	_	IN	_	_	_	_	_
8	atopic	_	_	JJ	_	_	_	_	_
9	dermatitis	_	_	NN	_	_	_	_	_
10	(	_	_	-LRB-	_	_	_	_	_
11	Table	_	_	NN	_	_	_	_	_
12	1	_	_	CD	_	_	_	_	_
13	)	_	_	-RRB-	_	_	_	_	_
14	based	_	_	VBN	_	_	_	_	_
15	on	_	_	IN	_	_	_	_	_
16	trehalose	_	_	NN	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	ceramides	_	_	NNS	_	_	_	_	_
19	based	_	_	VBN	_	_	_	_	_
20	ingredient	_	_	NN	_	_	_	_	_
21	is	_	_	VBZ	_	_	_	_	_
22	reported	_	_	VBN	_	_	_	_	_
23	below	_	_	RB	_	_	_	_	_
24	for	_	_	IN	_	_	_	_	_
25	illustrative	_	_	JJ	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	non-limiting	_	_	JJ	_	_	_	_	_
28	purposes	_	_	NNS	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	Purpose	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	test	_	_	NN	_	_	_	_	_
5	:	_	_	:	_	_	_	_	_
6	To	_	_	TO	_	_	_	_	_
7	provide	_	_	VB	_	_	_	_	_
8	active	_	_	JJ	_	_	_	_	_
9	substances	_	_	NNS	_	_	_	_	_
10	through	_	_	IN	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	form	_	_	NN	_	_	_	_	_
13	that	_	_	WDT	_	_	_	_	_
14	allows	_	_	VBZ	_	_	_	_	_
15	a	_	_	DT	_	_	_	_	_
16	prompt	_	_	JJ	_	_	_	_	_
17	release	_	_	NN	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	an	_	_	DT	_	_	_	_	_
20	effective	_	_	JJ	_	_	_	_	_
21	amount	_	_	NN	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	atopic	_	_	JJ	_	_	_	_	_
24	dermatitis	_	_	NN	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	characterized	_	_	VBN	_	_	_	_	_
27	by	_	_	IN	_	_	_	_	_
28	a	_	_	DT	_	_	_	_	_
29	deteriorated	_	_	VBN	_	_	_	_	_
30	functionality	_	_	NN	_	_	_	_	_
31	of	_	_	IN	_	_	_	_	_
32	the	_	_	DT	_	_	_	_	_
33	barrier	_	_	NN	_	_	_	_	_
34	,	_	_	,	_	_	_	_	_
35	an	_	_	DT	_	_	_	_	_
36	increased	_	_	VBN	_	_	_	_	_
37	transepidermal	_	_	JJ	_	_	_	_	_
38	water	_	_	NN	_	_	_	_	_
39	loss	_	_	NN	_	_	_	_	_
40	(	_	_	-LRB-	_	_	_	_	_
41	TEWL	_	_	NN	_	_	_	_	_
42	)	_	_	-RRB-	_	_	_	_	_
43	and	_	_	CC	_	_	_	_	_
44	a	_	_	DT	_	_	_	_	_
45	significant	_	_	JJ	_	_	_	_	_
46	xerosis	_	_	NN	_	_	_	_	_
47	,	_	_	,	_	_	_	_	_
48	as	_	_	RB	_	_	_	_	_
49	well	_	_	RB	_	_	_	_	_
50	as	_	_	IN	_	_	_	_	_
51	in	_	_	IN	_	_	_	_	_
52	the	_	_	DT	_	_	_	_	_
53	case	_	_	NN	_	_	_	_	_
54	of	_	_	IN	_	_	_	_	_
55	pathologies	_	_	NNS	_	_	_	_	_
56	associated	_	_	VBN	_	_	_	_	_
57	with	_	_	IN	_	_	_	_	_
58	a	_	_	DT	_	_	_	_	_
59	local	_	_	JJ	_	_	_	_	_
60	subcutaneous	_	_	JJ	_	_	_	_	_
61	microcirculation	_	_	NN	_	_	_	_	_
62	disorder	_	_	NN	_	_	_	_	_
63	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	efficacy	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	topical	_	_	JJ	_	_	_	_	_
6	cosmetic	_	_	JJ	_	_	_	_	_
7	formulation	_	_	NN	_	_	_	_	_
8	containing	_	_	VBG	_	_	_	_	_
9	trehalose	_	_	NN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	ceramides	_	_	NNS	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	comparison	_	_	NN	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	a	_	_	DT	_	_	_	_	_
16	placebo	_	_	NN	_	_	_	_	_
17	has	_	_	VBZ	_	_	_	_	_
18	been	_	_	VBN	_	_	_	_	_
19	evaluated	_	_	VBN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Mean	_	_	JJ	_	_	_	_	_
2	values	_	_	NNS	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	standard	_	_	JJ	_	_	_	_	_
5	deviations	_	_	NNS	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	variations	_	_	NNS	_	_	_	_	_
9	were	_	_	VBD	_	_	_	_	_
10	calculated	_	_	VBN	_	_	_	_	_
11	for	_	_	IN	_	_	_	_	_
12	each	_	_	DT	_	_	_	_	_
13	set	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	values	_	_	NNS	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	Following	_	_	VBG	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	results	_	_	NNS	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	normality	_	_	NN	_	_	_	_	_
6	test	_	_	NN	_	_	_	_	_
7	(	_	_	-LRB-	_	_	_	_	_
8	Kolmogorov	_	_	NNP	_	_	_	_	_
9	–	_	_	:	_	_	_	_	_
10	Smirnov	_	_	NNP	_	_	_	_	_
11	test	_	_	NN	_	_	_	_	_
12	)	_	_	-RRB-	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	instrumental	_	_	JJ	_	_	_	_	_
16	data	_	_	NN	_	_	_	_	_
17	(	_	_	-LRB-	_	_	_	_	_
18	T0	_	_	NNP	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	T4	_	_	CD	_	_	_	_	_
21	weeks	_	_	NNS	_	_	_	_	_
22	)	_	_	-RRB-	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	variations	_	_	NNS	_	_	_	_	_
26	(	_	_	-LRB-	_	_	_	_	_
27	T4	_	_	NNP	_	_	_	_	_
28	weeks-T0	_	_	NN	_	_	_	_	_
29	)	_	_	-RRB-	_	_	_	_	_
30	were	_	_	VBD	_	_	_	_	_
31	statistically	_	_	RB	_	_	_	_	_
32	compared	_	_	VBN	_	_	_	_	_
33	by	_	_	IN	_	_	_	_	_
34	means	_	_	NN	_	_	_	_	_
35	of	_	_	IN	_	_	_	_	_
36	t	_	_	NN	_	_	_	_	_
37	-test	_	_	NN	_	_	_	_	_
38	for	_	_	IN	_	_	_	_	_
39	parametric	_	_	JJ	_	_	_	_	_
40	and	_	_	CC	_	_	_	_	_
41	dependent	_	_	JJ	_	_	_	_	_
42	data	_	_	NNS	_	_	_	_	_
43	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	all	_	_	DT	_	_	_	_	_
3	cases	_	_	NNS	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	groups	_	_	NNS	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	data	_	_	NNS	_	_	_	_	_
9	were	_	_	VBD	_	_	_	_	_
10	considered	_	_	VBN	_	_	_	_	_
11	statistically	_	_	RB	_	_	_	_	_
12	different	_	_	JJ	_	_	_	_	_
13	for	_	_	IN	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	probability	_	_	NN	_	_	_	_	_
16	value	_	_	NN	_	_	_	_	_
17	p	_	_	NN	_	_	_	_	_
18	<	_	_	SYM	_	_	_	_	_
19	0.05	_	_	CD	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Protocol	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	double-blind	_	_	JJ	_	_	_	_	_
4	study	_	_	NN	_	_	_	_	_
5	:	_	_	:	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	product	_	_	NN	_	_	_	_	_
8	containing	_	_	VBG	_	_	_	_	_
9	trehalose	_	_	NN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	ceramides	_	_	NNS	_	_	_	_	_
12	ingredient	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	placebo	_	_	NN	_	_	_	_	_
16	was	_	_	VBD	_	_	_	_	_
17	applied	_	_	VBN	_	_	_	_	_
18	on	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	forearms	_	_	NNS	_	_	_	_	_
21	by	_	_	IN	_	_	_	_	_
22	20	_	_	CD	_	_	_	_	_
23	volunteers	_	_	NNS	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	either	_	_	DT	_	_	_	_	_
26	sex	_	_	NN	_	_	_	_	_
27	(	_	_	-LRB-	_	_	_	_	_
28	1	_	_	CD	_	_	_	_	_
29	male	_	_	NN	_	_	_	_	_
30	and	_	_	CC	_	_	_	_	_
31	19	_	_	CD	_	_	_	_	_
32	females	_	_	NNS	_	_	_	_	_
33	with	_	_	IN	_	_	_	_	_
34	an	_	_	DT	_	_	_	_	_
35	average	_	_	JJ	_	_	_	_	_
36	age	_	_	NN	_	_	_	_	_
37	of	_	_	IN	_	_	_	_	_
38	50	_	_	CD	_	_	_	_	_
39	years	_	_	NNS	_	_	_	_	_
40	)	_	_	-RRB-	_	_	_	_	_
41	with	_	_	IN	_	_	_	_	_
42	atopic	_	_	JJ	_	_	_	_	_
43	and	_	_	CC	_	_	_	_	_
44	very	_	_	RB	_	_	_	_	_
45	dry	_	_	JJ	_	_	_	_	_
46	skin	_	_	NN	_	_	_	_	_
47	(	_	_	-LRB-	_	_	_	_	_
48	xerosis	_	_	NN	_	_	_	_	_
49	)	_	_	-RRB-	_	_	_	_	_
50	,	_	_	,	_	_	_	_	_
51	twice	_	_	RB	_	_	_	_	_
52	a	_	_	DT	_	_	_	_	_
53	day	_	_	NN	_	_	_	_	_
54	,	_	_	,	_	_	_	_	_
55	for	_	_	IN	_	_	_	_	_
56	4	_	_	CD	_	_	_	_	_
57	weeks	_	_	NNS	_	_	_	_	_
58	.	_	_	.	_	_	_	_	_


1	During	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	subjects	_	_	NNS	_	_	_	_	_
6	were	_	_	VBD	_	_	_	_	_
7	instructed	_	_	VBN	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	wash	_	_	VB	_	_	_	_	_
10	their	_	_	PRP$	_	_	_	_	_
11	body	_	_	NN	_	_	_	_	_
12	using	_	_	VBG	_	_	_	_	_
13	their	_	_	PRP$	_	_	_	_	_
14	current	_	_	JJ	_	_	_	_	_
15	skin	_	_	NN	_	_	_	_	_
16	care	_	_	NN	_	_	_	_	_
17	regimen	_	_	NN	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	not	_	_	RB	_	_	_	_	_
21	apply	_	_	VB	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	tested	_	_	VBN	_	_	_	_	_
24	products	_	_	NNS	_	_	_	_	_
25	on	_	_	IN	_	_	_	_	_
26	any	_	_	DT	_	_	_	_	_
27	other	_	_	JJ	_	_	_	_	_
28	site	_	_	NN	_	_	_	_	_
29	than	_	_	IN	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	prescribed	_	_	VBN	_	_	_	_	_
32	ones	_	_	NNS	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	whole	_	_	JJ	_	_	_	_	_
4	duration	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	test	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	subjects	_	_	NNS	_	_	_	_	_
11	were	_	_	VBD	_	_	_	_	_
12	not	_	_	RB	_	_	_	_	_
13	allowed	_	_	VBN	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	use	_	_	VB	_	_	_	_	_
16	different	_	_	JJ	_	_	_	_	_
17	products	_	_	NNS	_	_	_	_	_
18	on	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	forearms	_	_	NNS	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	instructed	_	_	VBD	_	_	_	_	_
23	to	_	_	TO	_	_	_	_	_
24	avoid	_	_	VB	_	_	_	_	_
25	UV	_	_	NNP	_	_	_	_	_
26	exposure	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	Furthermore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	side	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	application	_	_	NN	_	_	_	_	_
7	(	_	_	-LRB-	_	_	_	_	_
8	left	_	_	VBN	_	_	_	_	_
9	or	_	_	CC	_	_	_	_	_
10	right	_	_	JJ	_	_	_	_	_
11	forearm	_	_	NN	_	_	_	_	_
12	)	_	_	-RRB-	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	two	_	_	CD	_	_	_	_	_
16	formulations	_	_	NNS	_	_	_	_	_
17	(	_	_	-LRB-	_	_	_	_	_
18	cream	_	_	NN	_	_	_	_	_
19	containing	_	_	VBG	_	_	_	_	_
20	trehalose	_	_	NN	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	ceramides	_	_	NNS	_	_	_	_	_
23	based	_	_	VBN	_	_	_	_	_
24	ingredient	_	_	NN	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	placebo	_	_	NN	_	_	_	_	_
27	)	_	_	-RRB-	_	_	_	_	_
28	were	_	_	VBD	_	_	_	_	_
29	randomized	_	_	VBN	_	_	_	_	_
30	among	_	_	IN	_	_	_	_	_
31	the	_	_	DT	_	_	_	_	_
32	volunteers	_	_	NNS	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	Each	_	_	DT	_	_	_	_	_
2	sample	_	_	NN	_	_	_	_	_
3	was	_	_	VBD	_	_	_	_	_
4	labeled	_	_	VBN	_	_	_	_	_
5	“	_	_	``	_	_	_	_	_
6	right	_	_	JJ	_	_	_	_	_
7	”	_	_	''	_	_	_	_	_
8	or	_	_	CC	_	_	_	_	_
9	“	_	_	``	_	_	_	_	_
10	left	_	_	NN	_	_	_	_	_
11	”	_	_	''	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	indicating	_	_	VBG	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	side	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	application	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	product	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	assignment	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	subject	_	_	NN	_	_	_	_	_
5	number	_	_	NN	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	subsequent	_	_	JJ	_	_	_	_	_
8	placement	_	_	NN	_	_	_	_	_
9	on	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	randomization	_	_	NN	_	_	_	_	_
12	chart	_	_	NN	_	_	_	_	_
13	were	_	_	VBD	_	_	_	_	_
14	made	_	_	VBN	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	order	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	appearance	_	_	NN	_	_	_	_	_
19	at	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	study	_	_	NN	_	_	_	_	_
22	center	_	_	NN	_	_	_	_	_
23	on	_	_	IN	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	first	_	_	JJ	_	_	_	_	_
26	day	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	products	_	_	NNS	_	_	_	_	_
3	were	_	_	VBD	_	_	_	_	_
4	given	_	_	VBN	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	subjects	_	_	NNS	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	anonymous	_	_	JJ	_	_	_	_	_
10	containers	_	_	NNS	_	_	_	_	_
11	which	_	_	WDT	_	_	_	_	_
12	did	_	_	VBD	_	_	_	_	_
13	not	_	_	RB	_	_	_	_	_
14	provide	_	_	VB	_	_	_	_	_
15	any	_	_	DT	_	_	_	_	_
16	information	_	_	NN	_	_	_	_	_
17	about	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	treatment	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	comparisons	_	_	NNS	_	_	_	_	_
3	evidenced	_	_	VBD	_	_	_	_	_
4	statistically	_	_	RB	_	_	_	_	_
5	significant	_	_	JJ	_	_	_	_	_
6	differences	_	_	NNS	_	_	_	_	_
7	between	_	_	IN	_	_	_	_	_
8	studied	_	_	VBN	_	_	_	_	_
9	ingredient	_	_	NN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	placebo	_	_	NN	_	_	_	_	_
12	for	_	_	IN	_	_	_	_	_
13	both	_	_	DT	_	_	_	_	_
14	parameters	_	_	NNS	_	_	_	_	_
15	(	_	_	-LRB-	_	_	_	_	_
16	hydration	_	_	NN	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	TEWL	_	_	NN	_	_	_	_	_
19	)	_	_	-RRB-	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	means	_	_	VBZ	_	_	_	_	_
3	that	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	improvements	_	_	NNS	_	_	_	_	_
6	observed	_	_	VBN	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	active	_	_	JJ	_	_	_	_	_
10	area	_	_	NN	_	_	_	_	_
11	were	_	_	VBD	_	_	_	_	_
12	statistically	_	_	RB	_	_	_	_	_
13	higher	_	_	JJR	_	_	_	_	_
14	than	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	improvements	_	_	NNS	_	_	_	_	_
17	observed	_	_	VBN	_	_	_	_	_
18	in	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	placebo	_	_	NN	_	_	_	_	_
21	area	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Instrumental	_	_	JJ	_	_	_	_	_
2	measurements	_	_	NNS	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	skin	_	_	NN	_	_	_	_	_
5	hydration	_	_	NN	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	transepidermal	_	_	JJ	_	_	_	_	_
8	water	_	_	NN	_	_	_	_	_
9	loss	_	_	NN	_	_	_	_	_
10	(	_	_	-LRB-	_	_	_	_	_
11	TEWL	_	_	NNP	_	_	_	_	_
12	)	_	_	-RRB-	_	_	_	_	_
13	were	_	_	VBD	_	_	_	_	_
14	performed	_	_	VBN	_	_	_	_	_
15	on	_	_	IN	_	_	_	_	_
16	a	_	_	DT	_	_	_	_	_
17	selected	_	_	VBN	_	_	_	_	_
18	area	_	_	NN	_	_	_	_	_
19	(	_	_	-LRB-	_	_	_	_	_
20	9	_	_	CD	_	_	_	_	_
21	cm2	_	_	NN	_	_	_	_	_
22	)	_	_	-RRB-	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	forearms	_	_	NNS	_	_	_	_	_
26	at	_	_	IN	_	_	_	_	_
27	the	_	_	DT	_	_	_	_	_
28	baseline	_	_	NN	_	_	_	_	_
29	and	_	_	CC	_	_	_	_	_
30	after	_	_	IN	_	_	_	_	_
31	4	_	_	CD	_	_	_	_	_
32	weeks	_	_	NNS	_	_	_	_	_
33	of	_	_	IN	_	_	_	_	_
34	treatment	_	_	NN	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_


1	Skin	_	_	NN	_	_	_	_	_
2	Hydration	_	_	NN	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	statistically	_	_	RB	_	_	_	_	_
3	significant	_	_	JJ	_	_	_	_	_
4	increase	_	_	NN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	mean	_	_	JJ	_	_	_	_	_
8	basal	_	_	JJ	_	_	_	_	_
9	values	_	_	NNS	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	skin	_	_	NN	_	_	_	_	_
12	hydration	_	_	NN	_	_	_	_	_
13	was	_	_	VBD	_	_	_	_	_
14	evidenced	_	_	VBN	_	_	_	_	_
15	after	_	_	IN	_	_	_	_	_
16	4	_	_	CD	_	_	_	_	_
17	weeks	_	_	NNS	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	application	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	both	_	_	CC	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	ceramides	_	_	NNS	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	trehalose	_	_	NN	_	_	_	_	_
26	based	_	_	VBN	_	_	_	_	_
27	ingredient	_	_	NN	_	_	_	_	_
28	cream	_	_	NN	_	_	_	_	_
29	and	_	_	CC	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	placebo	_	_	NN	_	_	_	_	_
32	product	_	_	NN	_	_	_	_	_
33	(	_	_	-LRB-	_	_	_	_	_
34	Table	_	_	NN	_	_	_	_	_
35	2	_	_	CD	_	_	_	_	_
36	)	_	_	-RRB-	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	statistically	_	_	RB	_	_	_	_	_
3	significant	_	_	JJ	_	_	_	_	_
4	difference	_	_	NN	_	_	_	_	_
5	between	_	_	IN	_	_	_	_	_
6	ceramides	_	_	NNS	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	trehalose	_	_	NN	_	_	_	_	_
9	based	_	_	VBN	_	_	_	_	_
10	ingredient	_	_	NN	_	_	_	_	_
11	cream	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	placebo	_	_	NN	_	_	_	_	_
14	product	_	_	NN	_	_	_	_	_
15	was	_	_	VBD	_	_	_	_	_
16	detected	_	_	VBN	_	_	_	_	_
17	after	_	_	IN	_	_	_	_	_
18	4	_	_	CD	_	_	_	_	_
19	weeks	_	_	NNS	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	treatment	_	_	NN	_	_	_	_	_
22	(	_	_	-LRB-	_	_	_	_	_


1	Figure	_	_	NN	_	_	_	_	_
2	4	_	_	CD	_	_	_	_	_


1	)	_	_	-RRB-	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	cream	_	_	NN	_	_	_	_	_
3	containing	_	_	VBG	_	_	_	_	_
4	trehalose	_	_	NN	_	_	_	_	_
5	and	_	_	CC	_	_	_	_	_
6	ceramides	_	_	NNS	_	_	_	_	_
7	based	_	_	VBN	_	_	_	_	_
8	ingredient	_	_	NN	_	_	_	_	_
9	is	_	_	VBZ	_	_	_	_	_
10	able	_	_	JJ	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	improve	_	_	VB	_	_	_	_	_
13	skin	_	_	NN	_	_	_	_	_
14	hydration	_	_	NN	_	_	_	_	_
15	if	_	_	IN	_	_	_	_	_
16	compared	_	_	VBN	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	placebo	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Transepidermal	_	_	NNP	_	_	_	_	_
2	Water	_	_	NN	_	_	_	_	_
3	Loss	_	_	NN	_	_	_	_	_
4	(	_	_	-LRB-	_	_	_	_	_
5	TEWL	_	_	NN	_	_	_	_	_
6	)	_	_	-RRB-	_	_	_	_	_

